GW Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
June 02, 2020 07:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress
May 11, 2020 16:00 ET
|
GW Pharmaceuticals plc
- Total revenue of $120.6 million - - Total Epidiolex® net product sales of $116.1 million - - Conference call today at 4:30 p.m. EDT – LONDON and CARLSBAD, Calif., May 11, 2020 (GLOBE NEWSWIRE) --...
GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020
May 01, 2020 07:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020
April 21, 2020 14:04 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing...
GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance
April 06, 2020 09:00 ET
|
GW Pharmaceuticals plc
- Descheduling will enable prescribing free of the previous Schedule V requirements - CARLSBAD, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the...
GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex
March 31, 2020 07:00 ET
|
GW Pharmaceuticals plc; Greenwich Biosciences
CARLSBAD, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines,...
GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)
March 13, 2020 07:00 ET
|
GW Pharmaceuticals plc
LONDON, March 13, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising cannabinoid...
JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome
March 02, 2020 11:13 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of...
GW Pharmaceuticals regains exclusive commercialisation rights to Sativex® (nabiximols) in the UK from Bayer
March 02, 2020 02:00 ET
|
GW Pharmaceuticals plc
CAMBRIDGE, United Kingdom and READING, United Kingdom, March 02, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (GW) and Bayer plc, the life science company, today announce that GW will regain...
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress
February 25, 2020 16:01 ET
|
GW Pharmaceuticals plc
- Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year - - Total Epidiolex® net product sales of $104.5 million for the fourth quarter and $296.4 million for...